Drugs / Bionetide
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06849973 | Mar → Nov 2024 | Rett syndrome | Biomed Industries, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06840496 | Sep 2026 → Sep 2027 expected | Rett syndrome | Biomed Industries, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bionetide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06840496 ↗ |
| Known as | NA-921 | “NA-921 (Bionetide) solution administered based on the subject's weight at Baseline, twice daily for 12 weeks” NCT06849973 ↗ |
| Route | Oral | “administered twice daily by mouth” NCT06840496 ↗ |